Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Improved survival of children and adolescents with classical Hodgkin lymphoma treated on a harmonised protocol in South Africa. Pediatr Blood Cancer. 2024 Jan; 71(1):e30712.
-
The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast Cancer. Oncologist. 2023 10 03; 28(10):e921-e929.
-
Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa. Cancer Med. 2023 07; 12(14):15515-15529.
-
The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma. PLoS One. 2023; 18(1):e0280044.
-
Diffuse Large B-Cell Lymphoma in the Public-Sector of Johannesburg, South Africa, in the Era of Widescale Antiretroviral Therapy Use. J Acquir Immune Defic Syndr. 2022 12 01; 91(4):335-342.
-
HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridisation to assess MYC gene copies. Ann Diagn Pathol. 2022 Jun; 58:151913.
-
Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood Adv. 2021 08 10; 5(15):2958-2964.
-
A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection. Breast Cancer Res Treat. 2020 Dec; 184(3):861-872.
-
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. Gynecol Oncol. 2020 10; 159(1):142-149.
-
Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet. 2020 04 11; 395(10231):1195-1207.